According to the Implementation Opinions on Promoting the Project of "Jiangxi Produces Excellent Products" (GGQXXXXXXJZ [2021] No. 31) and the Notice on Carrying out the First Selection of "Jiangxi Produces Excellent Products" (GGXXJZ [2021] No. 176), 136 products were determined to be the first "Jiangxi Produces Excellent Products" after enterprise application, recommendation by local competent departments, qualification review, expert review, seeking department opinions and publicity, and are now published.

On the morning of December 16, the first Jiangxi Provincial Press Conference on "Jiangxi Produces High quality Products" was held in Nanchang with the theme of "High end Manufacturing: Jiangxi Produces High quality Products". Zheng Zhengchun, a member of the Party Leadership Group and Deputy Director of the Department of Industry and Information Technology of Jiangxi Province, attended and introduced the first "Jiangxi Produces Fine Products". Gong Hong, director of the Science and Technology Department of the Provincial Department of Industry and Information Technology, Zhao Shanshan, deputy director of the Quality Development Bureau of the Provincial Market Supervision Bureau, and Chen Jinwen, president of the Provincial Institute of Industry and Information Technology, attended the conference and answered questions from reporters. The press conference was hosted by Xu Cheng, Deputy Director of the External Information Department of the Publicity Department of the Provincial Party Committee.

VV116 is an oral nucleoside anti COVID-19 candidate drug jointly developed by many domestic scientific research institutions, such as Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Wuhan Institute of Virology, Chinese Academy of Sciences, and Xinjiang Institute of Physical and Chemical Technology, Chinese Academy of Sciences. The preclinical pharmacodynamics study showed that VV116 had significant inhibitory activity against COVID-19 original virus strains and mutant strains, such as delta virus, in vitro. The scientific research team of researcher Shen Jingshan from Shanghai Institute of Materia Medica of the Chinese Academy of Sciences and the cooperative scientific research institutions found through the test on the adenovirus mouse model that oral administration of VV116 can reduce the virus titer below the detection limit, and can significantly improve the pathological changes of the lung tissue of experimental model animals. A series of pre clinical safety evaluation experiments showed that VV116 is safe and has no genetic toxicity.

On August 11, under the encouragement of the national new drug innovation policy, more and more pharmaceutical enterprises participated in the research and development of new drugs, and the number of approved innovative drugs increased significantly. It is particularly important to improve the success rate of clinical trials of new drugs, speed up the marketing of new drugs, and do a good job in the top-level design of clinical research integration of new drugs, operation control and application for listing.

At the press conference of the joint prevention and control mechanism of the State Council on December 31, 2020, Chen Shifei, Deputy Director of the State Food and Drug Administration, said that the State Food and Drug Administration had approved the registration application of the COVID-19 inactivated vaccine of Sinopharm Biotech Beijing in accordance with the law and conditions on the evening of December 30.

In the modern biopharmaceutical production workshop of Qilu Pharmaceutical Group Co., Ltd. located in Jinan, Shandong Province, China's first bevacizumab biological analog, Anda, is in full production. This drug, which is mainly used to treat advanced, metastatic or recurrent non-small cell lung cancer and metastatic colorectal cancer, broke the exclusive monopoly of foreign pharmaceutical giants on similar drugs in China for many years after its listing at the end of last year, greatly enhancing the accessibility and affordability of clinical drugs.